Purdue Pharma
6
36M
3
0.05
0.50
2
- Areas of investment
Summary
In 1892 was created Purdue Pharma, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Stamford. The venture was found in North America in United States.
The higher amount of exits for fund were in 2016. The important activity for fund was in 2008. The fund is constantly included in less than 2 deals per year. The real fund results show that this Corporate Investor is 20 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Purdue Pharma performs on 11 percentage points more the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Purdue Pharma, startups are often financed by Tichenor Ventures, HBM Healthcare Investments AG, Auven Therapeutics. The meaningful sponsors for the fund in investment in the same round are OUP (Osage University Partners), HBM Healthcare Investments AG, Tichenor Ventures. In the next rounds fund is usually obtained by Tichenor Ventures, HBM Healthcare Investments AG, Auven Therapeutics.
Among the various public portfolio startups of the fund, we may underline Kolltan Pharmaceuticals For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Pharmaceutical, Biotechnology. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
This organization was formed by George Frederick Bingham, John Purdue Gray.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 0
- Exits
- 2
- Rounds per year
- 0.05
- Follow on index
- 0.50
- Investments by industry
- Biotechnology (6)
- Pharmaceutical (5)
- Medical (3)
- Biopharma (2)
- Health Care (1)
- Investments by region
-
- United States (5)
- Peak activity year
- 2008
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Avg. valuation at time of investment
- 78M
- Group Appearance index
- 0.50
- Avg. company exit year
- 9
- Avg. multiplicator
- 1.61
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Kolltan Pharmaceuticals | 31 Jul 2008 | Biotechnology, Medical, Pharmaceutical | Early Stage Venture | 40M | United States, Connecticut, New Haven |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.